News | July 19, 2023
SEBI approves Piramal Pharma’s Rs 1,050-crore rights issue
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The company is one of the most profitable companies manufacturing speciality chemicals in India
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
The companies plan to use the proceeds to retire debt and expand operations
TCPCL is the largest and only commercial manufacturer of SDAs for zeolites in India
The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited
Sets price band at ?695 to ?735 per Equity Share
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)